Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year-Reference-Cited by-同舟云学术

Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year

Published:2016-04 Issue:4 Volume:7 Page:e168
ISSN:2155-384X
Container-title:Clinical and Translational Gastroenterology
language:en
Short-container-title:

Author:

Gibson Peter R,Feagan Brian G,Sandborn William J,Marano Colleen,Strauss Richard,Johanns Jewel,Padgett Lakshmi,Collins Judith,Tarabar Dino,Hebzda Zbigniew,Rutgeerts Paul,Reinisch Walter

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology

Link

http://www.nature.com/articles/ctg201624.pdf

Reference9 articles.

1. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.;Sandborn;Gastroenterology,2014

2. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.;Sandborn;Gastroenterology,2014

3. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis.;Rutgeerts;Aliment Pharmacol Ther,2015

4. Long-term infliximab maintenance therapy for ulcerative colitis: the act-1 and -2 extension studies.;Reinisch;Inflamm Bowel Dis,2012

5. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohns Relapse Prevention Trial Study Group.;Irvine;Gastroenterology,1994

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selection strategy of second-line biologic therapies in adult patients with ulcerative colitis following prior biologic treatment failure: Systematic review and meta-analysis;Pharmacological Research;2024-04

2. Emerging oral drug options for ulcerative colitis;Expert Opinion on Emerging Drugs;2023-07-03

3. Low Occurrence of Colectomy With Long-Term (up to 4 Years) Golimumab Treatment in Patients With Moderate-to-Severe Active Ulcerative Colitis: Data From the PURSUIT Maintenance and Long-Term Extension Studies;Crohn's & Colitis 360;2023-07-01

4. Guía GADECCU 2022 para el tratamiento de la colitis ulcerosa. Adaptación y actualización de la Guía GETECCU 2020;Gastroenterología y Hepatología;2023-03

5. Management of Concomitant Inflammatory Bowel Disease or Uveitis in Patients With Psoriatic Arthritis: An Updated Review Informing the 2021 GRAPPA Treatment Recommendations;The Journal of Rheumatology;2022-12-01